IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells.
Fu Z, Huang Z, Xu H, Liu Q, Li J, Song K, Deng Y, Tao Y, Zhang H, Wang P, Li H, Sheng Y, Zhou A, Han L, Fu Y, Wang CZ, Choudhary SK, Ye K, Veggiani G, Li Z, August A, Huang W, Shan Q, Peng H.
Fu Z, et al. Among authors: peng h.
J Clin Invest. 2024 Nov 26:e178558. doi: 10.1172/JCI178558. Online ahead of print.
J Clin Invest. 2024.
PMID: 39589809